Grifols S.A. is a leading global biopharmaceutical company specializing in the collection, processing, and transformation of human plasma into life-saving medicines. Founded in 1909 and headquartered ... Grifols S.A. is a leading global biopharmaceutical company specializing in the collection, processing, and transformation of human plasma into life-saving medicines. Founded in 1909 and headquartered in Barcelona, the firm operates across four main business lines: Bioscience, Hospital, Diagnostic, and Raw Materials. The Bioscience division is particularly notable for its focus on developing therapeutic products derived from plasma, which are essential for treating chronic and rare conditions such as immune deficiencies and bleeding disorders. Grifols maintains a significant manufacturing presence with production facilities in Europe, the United States, Mexico, and Australia, and distributes its products to more than 100 countries. By directly operating plasma donation centers worldwide, Grifols has established itself as one of the largest plasma companies, supporting resilient supply chains and innovation in transfusion medicine. The company employs more than 23,000 people and holds a strong reputation within the health technology sector, underpinning its substantial role in the global pharmaceuticals market.